自引率: 1.3%
被引量: 9427
通过率: 暂无数据
审稿周期: 6
版面费用: 暂无数据
国人发稿量: 6
投稿须知/期刊简介:
Cancer Treatment Reviews is an international journal that helps keep both the clinician and researcher abreast of developments in cancer treatment research throught the publication of state-of-the-art, authoritative reviews. Every review emphasises the interdisciplinary nature of each topic, acquainting the reader with the wide range of approaches to cancer treatment including: surgery, radiotherapy, chemotherapy, immunotherapy, and combined approaches Each issue provides topical reviews under the following regular sections: comments on controversy, tumor reviews, anti-tumor treatments, new drugs, complications of treatment, general and supportive care, laboratory/clinic interface. Indexed by Index Medicus, Medline, Current Contents/ Clinical Medicine, Science Citation Index, Sci Search, Indexed to Scientific Review, Research Alert and Medical Documentation Service.
期刊描述简介:
Cancer Treatment Reviews is an international journal that helps keep both the clinician and researcher abreast of developments in cancer treatment research throught the publication of state-of-the-art, authoritative reviews. Every review emphasises the interdisciplinary nature of each topic, acquainting the reader with the wide range of approaches to cancer treatment including: surgery, radiotherapy, chemotherapy, immunotherapy, and combined approaches Each issue provides topical reviews under the following regular sections: comments on controversy, tumor reviews, anti-tumor treatments, new drugs, complications of treatment, general and supportive care, laboratory/clinic interface. Indexed by Index Medicus, Medline, Current Contents/ Clinical Medicine, Science Citation Index, Sci Search, Indexed to Scientific Review, Research Alert and Medical Documentation Service.
-
Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.
被引量：- 发表：1970
-
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation.
被引量：- 发表：1970
-
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes.
被引量：- 发表：1970
-
Bone complications of cancer treatment.
被引量：- 发表：1970
-
Precision medicine for multiple myeloma: The case for translocation (11;14).
The t(11;14) translocation is among the most prevalent cytogenetic abnormalities in multiple myeloma (MM), distinguished by its unique features and biology that have been thoroughly explored for decades. What further sets this MM subtype apart is its oscillating prognostic significance, from initially being considered a favorable alteration to intermediate risk and potential future reclassification as favorable risk. Despite not being inherently a high-risk alteration indicative of an aggressive phenotype, it appears that t(11;14)-MM is less responsive to novel agents like proteasome inhibitors and immunomodulatory drugs which have otherwise transformed the disease's treatment landscape, perhaps partially explained by its reduced propensity for immunoglobulin production and oligosecretory nature. However, its distinct reliance on Bcl-2 has heightened its sensitivity to venetoclax. Further subclassification based on morphological and genomic characteristics could enhance our prediction models of treatment responses and enable more tailored therapeutic strategies for patients. This review aims to encapsulate the existing research evidence in this area.
被引量：- 发表：1970
